CD8A and cancer: Collectively, these data further strengthen our notion that the proportion of DP pTemra is inversely correlated with the immunogenic potential of tumor antigens (ie, TMB) and the number of CD8+ TILs, providing valuable clinical implication for predicting response outcome of patients receiving cancer immunotherapy.36–39